Related Experiment Video

Updated: Sep 10, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K

Barnidipine real-life tolerability in arterial hypertension: results from the BASIC-HT study

R Lins, P Marckx, R Vandebeek

    Acta Clinica Belgica
    |March 28, 2015
    PubMed

    Insights

    Barnidipine, a calcium channel blocker, demonstrated good tolerability and adherence in hypertensive patients. This led to significant blood pressure reduction in a real-world setting.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Essential hypertension management is often hindered by poor patient adherence to medication.
    • Effective treatments require a balance of efficacy and tolerability.
    • Barnidipine, a lipophilic calcium channel blocker, offers comparable efficacy to other dihydropyridines.

    Purpose of the Study:

    • To evaluate the real-world tolerability of barnidipine in a large essential hypertension patient cohort.
    • To assess the efficacy of barnidipine in a clinical practice setting.

    Main Methods:

    • An observational study involving 20,479 patients with essential hypertension.
    • Tolerability and efficacy were assessed over a 3-month period across two visits.
    • Analysis included 20,275 patients.

    Main Results:

    • Adverse events occurred in 10.6% of patients, with 3% discontinuing treatment due to adverse events.
    • Expected adverse events associated with calcium channel blockers were observed.
    • The overall dropout rate was 8%.
    • Mean systolic blood pressure decreased from 159.6 to 138.2 mmHg, and diastolic blood pressure decreased from 92.5 to 81.7 mmHg.

    Conclusions:

    • Barnidipine treatment resulted in a significant reduction in blood pressure.
    • Improved patient adherence to barnidipine therapy is likely responsible for the observed blood pressure decrease.
    Abstract

    Keywords:
    Barnidipine,Calcium channel blockers,Hypertensive patient,Observational study,Persistence

    More Related Videos

    Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model08:51

    Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model

    Published on: November 11, 2022

    2.1K
    Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug05:57

    Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

    Published on: May 17, 2024

    1.3K

    Related Concept Videos

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

    β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
    Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

    Adrenergic Antagonists: ɑ and β-Receptor Blockers

    Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
    Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

    Antihypertensive Drugs: Angiotensin II Receptor Blockers

    In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
    Antihypertensive Drugs: Direct Renin Inhibitors01:25

    Antihypertensive Drugs: Direct Renin Inhibitors

    The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...